OOIR: Observatory of International Research

Papers

(The TQCC of Alzheimers & Dementia is 0. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-04-01 to 2025-04-01.)

Article	Citations
Dissecting the Neuropathological Contributors to Rapidly Progressive Dementia	1791
Effect of aging and neurodegeneration on contextual processing	1582
Differences in the brain transcriptome of glial genes due to aging and active DNA Aβ42 and passive MOAB anti‐Aβ immunotherapy in the 3xTg‐AD mouse strain	701
	437
Neurochemical signs of astrocytic and neuronal injury in acute COVID‐19 normalizes during long‐term follow‐up	434
Higher ACE2 expression in the brains of individuals with Alzheimer’s disease	410
Transgender adults report greater cognitive and related functional challenges: Findings from the 2015‐2019 Behavioral Risk Factor Surveillance System	338
Tau pathology progression across PET‐based stages of regional amyloid deposition	230
Using deep learning models to examine the biological impact of polygenic risks for Alzheimer’s disease	218
Predicting Alzheimer’s disease progression in healthy and MCI subjects using multi‐modal deep learning approach	192
MIND and Mediterranean diet association with Alzheimer’s disease pathology	182
Smartphone ownership and usage in Chinese‐ and English‐speaking older adults	156
	153
EEG biomarkers differentiate Lewy body dementia from Alzheimer’s disease	153
Neuroinflammation in COVID‐19 and ADRD: Similarities, differences, and interactions	144
Tau deletion or loss of function promotes peripheral insulin resistance	144
Visual memory test equal to commonly used verbal memory test in predicting tau in the medial temporal lobe	143
The roles atherosclerotic cardiovascular disease risk and depression on cognitive outcomes in Mexican Americans and non‐Hispanic whites	140
Apathy across neurodegenerative disorders is associated with sex‐specific changes in sub‐cortical and cortical grey matter volumes	136
Is item response theory superior to classical test theory in scoring A‐IADL?	129
Associations among clinical characteristics of sleep quality, cognitive performance, and brain architecture in Thai dementia spectrum disorders	125
Objective subtle cognitive decline is associated with a more rapid increase in plasma phosphorylated‐tau181 levels over time	123
Reliability and participant acceptance of remotely administered RBANS in an MCI and Alzheimer’s disease cohort	115
Differences in sex distribution between genetic and sporadic FTD	114
Ten‐minute cognitive screening tool for mild cognitive impairment and prediction of pathological ß‐amyloid	113

Performance on autobiographical memory tests measuring contextual details is impaired in subjective cognitive decline and mild cognitive impairment	110
Late‐onset epileptic seizures in adults with Down syndrome are linked to Alzheimer’s disease	110
Dementia‐related agitation in Portuguese public hospitals: A retrospective analysis of 6,586 hospitalization episodes	107
Neurodegenerative diseases and lifetime seizure risk: A study of autopsy proven cases	104
Trajectories of self‐rated concerns in individuals developing cognitive decline	102
A stepwise approach towards diagnostic workup in dementia using online cognitive tools	102
Neurocognitive effects of immune checkpoint inhibitors: A literature review	102
Analysis of the ACE‐R’s sub‐items that best differentiate healthy controls, amnestic MCI and non‐amnestic MCI	101
Serious mini‐games for cognitive function assessment	99
Non‐fluent/agrammatic variant of primary progressive aphasia with progressive supranuclear palsy	99
Self‐reported and informant‐reported depressive symptoms are independent and divergent predictors of new onset dementia in older adults	89
Brain health actions: Evidence from the electronic Person‐Specific Outcome Measure (ePSOM) development programme	86
Adjustment to test, risk and diagnostic disclosures in people with mild cognitive impairment: An observational cohort study	85
Age‐dependent functional connectivity changes across large‐scale brain networks disrupt memory consolidation processes	84
Cognition may improve with medium‐chain triglyceride oil supplementation: A pilot study	83
Visual memory scores are associated with lateralization of tau in the medial temporal lobe	79
At‐home assessment of cognitive performance: Establishing norm scores for the Cognitive Online Self‐Test Amsterdam (COST‐A)	78
The effect of plasmalogen precursor supplementation on blood plasmalogen and C‐reactive protein levels and cognition in cognitively impaired persons	77
Social cognition provides early distinction between phenocopy syndrome of behavioural variant frontotemporal dementia and behavioural variant frontotemporal dementia	77
Examination of cognitive performance and mild behavioral impairment domains of apathy, mood, impulse dyscontrol, social inappropriateness and psychosis in cognitively normal adults aged 50 and over	76
Associations between obstructive sleep apnea, Alzheimer’s disease pathology, and objective daytime sleepiness measured by the psychomotor vigilance task in cognitively unimpaired adults	75
Does higher educational attainment influence functional capabilities among African Americans with Alzheimer’s disease?	71
Aetiology and prognosis of the motoric cognitive risk syndrome: A population‐based comparison with mild cognitive impairment	70
MRI and CSF markers of mild behavioural impairment: Findings from the MEMENTO cohort study	70
Utility and usability of brief, remote, and self‐administered cognitive assessment for older adults with intact cognition and mild cognitive impairment: A novel approach to increase access during the	69
The heterogeneity of subjective cognitive decline: A data‐driven approach on a population‐based sample	65
Precognize pilot study: A visuomotor ability‐based novel screening method for Alzheimer’s disease?	62
High‐fat diet reduced dendritic spine density, but it did not affect cognitive function in spontaneous diabetic torii rats	60
Neurovascular unit dysfunction in Alzheimer’s disease	58
Lauric acid prevents the production of IL‐8 and IL‐13 and the increase of kynurenine/tryptophan ratio in LPS‐stimulated human astrocytes	58
Associations of automatically segmented, enlarged perivascular spaces with neuropathology and cognition in community‐based older adults	57
Defects in the autophagy lysosomal pathway in a cell model of disease‐associated tau	57
Progress towards brain organoid models with representative neurovascular features	56
Neuropathologic correlates of shape of subcortical brain structures	56
Developments in understanding early onset Alzheimer's disease	55
Modulation of the Immunoproteasome Affects Pathological Tau Aggregation in Alzheimer’s Disease	55
LDs in AD: Lipid Droplet Dynamics are Modulated by APOE	54
Spatial transcriptomics identifies disrupted circadian gene expression in a mouse model of Alzheimer’s disease	54
Amyloid and tau fibrils induce different microglial phenotypes but converge to similar altered molecular processes	53
Deletion of microRNA‐21 exacerbates multiple phenotypes associated with Alzheimer’s disease through the RECK and ADAM10 pathway in a mouse model of Aβ amyloidosis	53
Administration of mitochondrial fusion promoter during ischemia and at the onset of reperfusion exert neuroprotective effects in rats with cardiac ischemia/reperfusion injury	52
Mechanistic insights into the therapeutic potential of Angiotensin type 2 receptors (AT2R) in shaping behavior of astrocytes and microglia during hypertensive state	52
The role of the blood‐brain barrier in brain insulin signaling	51
Long term high‐fat feeding induces cognitive impairment, alterations in microglial morphology, and spatial transcriptomic changes	50
Characteristics of AD‐brain tau aggregate internalisation by human astrocytes and the responses induced	49
Activation of Wnt/β‐catenin pathway in the brain endothelium mitigates Aβ‐induced blood‐brain barrier dysfunction in Alzheimer’s disease	49
Pseudo‐longitudinal trajectories of cerebrovascular disease biomarkers in adults with Down syndrome across the lifespan	49
Mitochondrial Localized Amyloid Precursor Protein Alters Mitochondrial Function and Mitophagy	48
Understanding the role of the mitochondrial AD risk gene LACTB in myeloid cells.	48
Neuroprotective potential of safinamide mesylate in streptozotocin induced sporadic Alzheimer’s disease in rats	48

Protective effects of gestational folic acid and egg yolk powder solution intubation on motor coordination, anxiety, cognition, acetylcholinesterase activity and DNA fragmentation in prenatal alcohol	47
Role of Onset of Diabetes on Development of Cognitive Impairment in Rats	47
Longitudinal white matter hyperintensities in Down’s syndrome	47
FERMT2 cleavage impacts APP metabolism in a Src‐dependent manner	46
GM1 modulates amyloid‐beta activation of NLRP3 inflammasome in microglia through Akt/mTOR‐mediated regulation of autophagy	46
Progressive dysregulation of circular RNAs in the hippocampus of a transgenic mouse model of amyloidosis	46
All‐in‐Human Target Discovery in Alzheimer’s Disease and Resilient Brains	46
Elucidating Cell Diversity and Functions of Human Brain Borders in Alzheimer’s Disease	45
Syzigium aromaticum may protect against paraquat mediated toxicity via p53 and Sestrin2 modulation	45
Myeloid Differentiation Factor 2 Inhibition Protects Against Doxorubicin‐induced Microglial Activation and Senescence	45
Differential Effects of Anticholinergic Medications in a Human Neuronal Model of AD	45
Alzheimer’s disease induces pathological changes in the lungs of humans and the App^NL‐G‐F mouse model	45
Chronic kidney disease is associated with cognitive dysfunction and cardiovascular remodeling in aged male and female Sprague‐Dawley rats	44
Association between plasma inflammatory biomarkers and [¹⁸F]FDG‐PET signal in a transgenic amyloid rat model	44
Longitudinal Quantification of Sub‐Regional Hippocampal Amyloid‐Beta Burden in Ex‐Vivo slices from the App^NL‐G‐F Mouse Model of Alzheimer’s Disease	44
Lack of TREM2 and TYROBP effects on microglial homeostasis, activation and disease	44
Influence of physiological glucose levels on SIM‐A9 microglial cell immune response	43
ApoE4 is associated with higher lipid peroxidation but not protein nitration in AD brains	43
SORL1 regulates tau trafficking	43
Early loss of microglial p38α MAPK in the APPswe/PS1dE9 mouse model of Alzheimer’s disease alters soluble amyloid beta and reduces microglia co‐localization with amyloid plaques without affecting amyl	43
iPSC‐derived cortical neurons of sporadic Alzheimer’s disease patients reflect their clinical vulnerability	42
NETS‐seq advances the understanding of neuronal vulnerability in AD progression facilitating the identification of novel therapeutic targets at the single cell type level	42
A novel role for APP in neural circuit function	42
Statin therapy reduces the risk of AD: Clinic to bench translation for protective mechanism	42
Roles of HDAC6 in the pathogenesis of Alzheimer’s disease	42
Glutamate Release and Uptake in CNS of Young and Aged Mice Compared to a Knock‐In Mouse Model of Alzheimer’s Disease	41
Fibrillar tau induces blood brain barrier permeability, endothelial cell activation and bioenergetic alterations	41
PSEN2 poison exon inclusion is common across brain regions in late‐onset Alzheimer’s disease	41
Ex vivo identification of transcriptional regulation landscape and potential therapeutic targets against ER stress using Alzheimer’s disease patient‐derived dermal fibroblast: findings from BICWALZS c	41
Multiomics of iPSC‐derived ApoE3‐ and ApoE4 astrocytes and microglia uncovers cell type specific dysregulation of immunometabolism	41
Use of Inflammatory Panels to Distinguish Alzheimer’s Disease in a Down Syndrome Population	41
Neuronal SIRPα modulates disease pathology and progression in a mouse model of Alzheimer’s disease	40
Understanding the molecular mechanisms of TDP‐43 neurotoxicity in ALS and FTD to inspire targeted therapies	40
Issue Information	40
Role of primary cerebrovascular cilia in the pathogenesis of blood pressure and Alzheimer’s disease manifestations	40
Herpes Simplex Virus‐1 Proteins Drive Alzheimer’s Disease Pathologies in Humans	40
Transient CSF1R Inhibition in the Early Stage of AD Retains Homeostatic Microglia with Reduced Inflammasomes and Increased autophagy in the 5XFAD Model	40
NEUROPROTECTIVE EFFECT OF PERILLYL ALCOHOL IN EXPERIMENTAL SPORADIC AD	39
Functional investigation of the gliovascular niche‐related genes and their relevance to Alzheimer’s disease pathomechanisms in zebrafish	38
Neuroprotective Potential of Limonene in LPS induced Parkinson’s Disease in Rats	38
Hsp40 molecular chaperones are potent regulators of tau seeding and accumulation	38
Ascorbate insufficiency disrupts neuronal transmission by surface electroencephalogram in a mouse model of Alzheimer’s disease	38
Regulation of meningeal lymphatic function by APOE	38
Comparative Toxicogenomics Database: A tool to investigate the effects of environmental exposures on the etiology of Alzheimer’s disease	38
APOEe4*TREM2 and sickle cell trait in a late onset Alzheimer’s disease mouse model	38
Overview on epidemiology and neuropathologic staging of limbic‐predominant age‐related TDP‐43 encephalopathy neuropathologic changes (LATE‐NC)	37
Lifestyle Modification Exerts Protection Against Obesity‐Induced Neurodegeneration Via CD147‐Related Mechanism	37
Ameliorative effects of Aqueous Fruit Pulp Extracts of Adansonia digitata on the Hippocampus of Aluminium Chloride‐treated Adult Wistar Rats	37
The role of Alzheimer’s risk factor ApoE4 on intracellular Aβ aggregation	37
B cell and T cell populations are altered in the brain‐draining lymph nodes of the senescence accelerated mouse prone 8 (SAMP8)	37
TNFα‐mediated inflammation in mouse models of VCID	37
A comparative study of medication profiles from AD, MCI, and non‐demented patients	37
Nanobodies: a promising tool to perturb ApoE4 activity in Alzheimer’s disease pathology	36
Serine‐129 phosphorylation of α‐synuclein is a trigger for physiologic protein‐protein interactions and synaptic function	36
A3 receptor as a target for the treatment of Alzheimer’s disease	36
Vagus Nerve Stimulation Provides Neuroprotection Against Doxorubicin‐induced Chemobrain Via Activations of Both Muscarinic and Nicotinic Acetylcholine Receptors	36
Role of Peroxiredoxin 6 in the Development of Tau Pathology	36
Understanding the protective effect of the PLCG2 P522R variant in human microglia	36
Amyloid beta and tau pathology compared within different Alzheimer’s disease mouse models after inoculation with Alzheimer’s disease brain tissue	35
Investigating two pore potassium channel THIK‐1 expression in Alzheimer’s disease	35
Adaptive immune response in Alzheimer’s disease: untangling the role of ApoE4	35
Olfactory Mucosal Cells of Individuals with Alzheimer’s Disease Display Alterations Similar to the Alzheimer Brain	35
Depletion of microglia with CSF1R inhibitor prevents tau aggregation in the mouse model Thy1P301S	35
Mutation in presynaptic protein Bassoon induces tauopathy in vivo	34
Reduced density of serotonergic axons without prominent neuron loss or tau pathology in the dorsal raphe nucleus in App knock‐in mouse models of amyloid‐β pathology	34
The role of Kir6.2‐KATP channels in modulating sleep, brain metabolism, and neuronal excitability in AD	34
Investigating the role of ketogenic conditions on cholesterol metabolism and neuroinflammation in APOE4 carriers	34
Genetic and pharmacologic proteasome augmentation ameliorates Alzheimer’s‐like pathology in animal models of AD	34
Leveraging the full potential of Raman spectroscopy for the identification of amyloid aggregation states	34
Amyloid‐β Pathology Exacerbates Aging‐Induced Dysregulation of C1q Expression in Cortical Neurons	34
Prevention of release of amyloid beta 1‐42 fibrils by inhibiting Hsc70	34
Lipopolysaccharide aggravates depressive‐like behavior via increasing microglial inflammation, decreasing microglial ramification, and altering tryptophan level in obese rats	34
Pharmacologically targeted mitochondrial fission/fusion performs neuroprotection against trastuzumab‐induced cognitive deficits in rats via suppressing mitochondrial dysfunction and oxidative stress	34
SARS‐CoV‐2 infection worsens Vascular Dementia (VaD)‐associated neuropathology in mice	34
Identification of a Novel Mechanism Fostering the Alterations of Brain Energy Metabolism: a Link Between AD and T2DM	34
Repetitive transcranial magnetic stimulation increases synaptic plasticity of cortical axons in the APP‐PS1 mouse model of amyloidosis	33
Observations on biomarkers in Roche Abeta‐targeting monoclonal antibody trials	33
A systematic evaluation of hippocampal GABA levels in transgenic mouse models of amyloid and tau	33
Lecanemab: Amyloid Reduction and Evidence of Downstream Biomarker Modification	33
The effect of memantine on cortical network function in frontotemporal lobar degeneration is conditional on baseline GABA physiology	32

Increased CRP and triglyceride level associate with accelerated progression of Alzheimer's disease	32
Proton pump inhibitors and dementia: A nationwide population‐based study	32
Extensive genetic and phenotypic description of MAPT p.R406W in the Flanders‐Belgian population	32
Development and assessment of analytic methods to improve the measurement of cognition in longitudinal studies of aging through the use of substudies with comprehensive neuropsychological testing	32
From research to realization: How a Texas health plan implemented an academic model of care for Alzheimer's disease	32
	32
APOE ε4–associated downregulation of the IL‐7/IL‐7R pathway in effector memory T cells: Implications for Alzheimer's disease	31
Association of cortical morphology, white matter hyperintensity, and glymphatic function in frontotemporal dementia variants	31
Neuroimaging correlates of Alzheimer's disease biomarker concentrations in a racially diverse high‐risk cohort of middle‐aged adults	31
The utility of recruitment incentives in early Alzheimer's disease trials	31
Prospects and challenges in using neuronal extracellular vesicles in biomarker research	31
	31
Psychosocial implications of learning amyloid PET results in an observational cohort	31
Altered Gut Microbiota in Dementia and Mild Cognitive Impairment in Community‐Dwelling Older Adults in Taiwan	30
Characterization of glial responses in Alzheimer’s disease with cyclic multiplex fluorescent immunohistochemistry and machine learning	30
Long‐term impact of type 2 diabetes onset on dementia incidence rate among New Zealanders with impaired glucose tolerance: A tapered‐matched landmark analysis over 25 years	30
Artificial intelligence for dementia drug discovery and trials optimization	30
Plasma amyloid beta predicts conversion to dementia in subjects with mild cognitive impairment: The BALTAZAR study	30
Leptin bioavailability and markers of brain atrophy and vascular injury in the middle age	30
Association of cancer history with structural brain aging markers of Alzheimer's disease and related dementias risk	30
The impact of built and social environmental characteristics on incidence and estimated risk of dementia	30
MRI CHANGES FOLLOWING TREATMENT OF GLP‐1 ANALOGUE, LIRAGLUTIDE IN ALZHEIMER’S DISEASE	30
Proteins translated from tau circular RNAs as drivers for Alzheimer’s disease and frontotemporal dementia	29
	29
Body mass index predicts lower connectivity in associational fibers of the temporal lobe in older men	29
Melatonin, metformin, and ranolazine equally improved cognitive function in rats with doxorubicin‐induced chemobrain	29
Racial‐ethnic differences in baseline and longitudinal change in neuropsychological test scores in the NACC Uniform Data Set 3.0	29
Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring announces new editor‐in‐chief for open access, peer reviewed journal	29
The MINT Sprint 2.0: A picture naming test for detection of naming impairments in Alzheimer's disease and in preclinical AD	29
Conversations and decision‐making about nutrition and hydration for people with severe dementia in acute hospitals: a qualitative study	29
Echocardiographic measures of the left heart and cerebrospinal fluid biomarkers of Alzheimer's disease pathology in cognitively intact adults: The CABLE study	28
HMGB1‐Mediated Senescence and Brain Inflammation Contributes to Cognitive Dysfunctions	28
Neuronal loss of the nucleus basalis of Meynert in primary progressive aphasia is associated with Alzheimer's disease neuropathological changes	28
Cis p‐tau underlies vascular contribution to cognitive impairment and dementia, but is effectively targeted by immunotherapy	28
Long‐term exposure to air pollution and road traffic noise and incidence of dementia in the Danish Nurse Cohort	28
Lack of bidirectional association between age‐related macular degeneration and Alzheimer's disease: A Mendelian randomization study	28
Associations of Sensory and Motor Functions in Midlife with Longitudinal Blood‐Based Biomarker Levels of Alzheimer’s Disease and Neurodegeneration	28
Plasma Aβ 42:40 ratio tracks with changes in brain amyloid PET SUVr in the core and open label extension of the phase 2 proof of concept study ban2401‐g000‐201 following treatment with lecanemab in su	28
	28
Impact of off‐target signal on longitudinal FTP quantification	28
Unique brain iron profiles associated with logopenic progressive aphasia and posterior cortical atrophy	28
Cerebrovascular injury markers explain the effect of systemic vascular risk on cognitive decline in older adults with lower amyloid burden	27
The impact of hypertension on longitudinal cognitive decline in cognitively unimpaired individuals	27
Developing early vulnerable area aggregates for PET detection of beta‐amyloid based on young and middle‐aged adults from the Framingham Heart Study	27
Lower white matter hyperintensity is associated with lower mild behavioral impairment severity among pre‐dementia people with higher education attainment	27
Longitudinal trajectories in clinical progression of Alzheimer’s disease tau positron emission tomography subtypes	27
Microglial activation might protect against accumulation of Aβ and tau aggregates over time in non‐demented Aβ‐positive individuals	27
Genetic Risk Score for Alzheimer’s Disease Predicts Brain Volume Differences in Mid‐ and Late‐life in UK Biobank Participants	27
APOE2 is associated with amyloid independent effects on tau PET signal in preclinical AD	27
Associations Between Age, Hippocampal Volume, and Spatial Working Memory in Periadolescent Children: Preliminary Findings from the PRANK Study	27
What's in a name?	26
Steps towards the implementation of amyloid‐PET in memory clinics: AMYPAD Diagnostic and Patient Management Study	26
Dopaminergic and noradrenergic integrity are differentially associated with late‐life memory performance	26
Plasma amyloid β 42/40 associations on episodic memory: Moderations with depressive symptoms and marital status	26
Neuroinflammation is associated with the rising of early Alzheimer’s disease pathology in amyloid‐negative elderly	26
Amyloid PET in the Lewy Body disease continuum	26
Age‐at‐Onset and APOE Related Heterogeneity in the Clinical, Plasma Biomarker, and Neuropathologic Presentation of Alzheimer’s Disease (AD)	26
Toward comprehensive value assessment for Alzheimer's disease innovations	26
Correlations and associations between fluid‐based and morphometric imaging biomarkers through interrogation and integration of data and analysis across two data platforms	26
Building the Research Path for Identifying and Validating Cognition‐related Digital Biomarkers	26
Identifying lifestyle factors that promote brain resilience in ApoE4 carriers	26
Age‐related tau‐PET uptake and its downstream effects extend beyond the medial temporal lobe in cognitively normal older adults	26
From identification to implementation: state of the art in biomarkers for immune function in CSF and blood	25
Associations of Amyloid, White Matter Hyperintensities, and Hippocampal Volume with Cognitive Trajectories in the Oldest‐Old: The 90+ Study	25
Multi‐modal biomarkers improve prediction of memory function in cognitively unimpaired older adults	25
Head‐to‐Head Comparison of Four Plasma Phospho‐Tau Immunoassays in the Neuropathological Diagnosis of Alzheimer’s Disease	25
Roadmap to implementation of a fully automated blood‐based biomarker test to facilitate diagnosis and treatment in early Alzheimer’s disease	25
In Vivo Head‐To‐Head Comparison of [¹⁸F]GTP1 and [¹⁸F]PI2620 in Alzheimer’s Disease	25
Cerebral Small Vessel Disease and Gait Speed in Older Adults without Dementia	25
Capturing Morphometric Patterns of Alzheimer's Disease Progression with a TV‐L1 Ordinal Machine Learning Model	25
Combining high‐resolution ex vivo MRI and histopathology to identify medial temporal lobe atrophy patterns specific to tau pathology in Alzheimer’s Disease	25
Identification of sex‐specific genetic variants associated with tau‐PET	24
Problems using structural MRIs from the oldest‐old, and some solutions: Lessons learned from The 90+ Study and ADNI	24
Early termination of pivotal trials in Alzheimer's disease—Preserving optimal value for participants and science	24
Plasma Markers of Neurodegeneration Associated with Postoperative Delirium in an Older Elective Arthroplasty Population	24
MRI‐guided Clustering of Alzheimer’s Disease patients: A post‐hoc analysis of Phase 3 Trial of Solanezumab for Mild Dementia Due to Alzheimer’s Disease	24
Suboptimal sleep efficiency and duration predicts rate of accumulation of Aβ‐ Amyloid in cognitively normal older adults	24
Medial temporal atrophy in posterior cortical atrophy and its relationship to the cingulate island sign	24
Novel Diagnostic ⁶⁴Cu PET Imaging Agents for Alzheimer’s Disease	24
Nurr1 and Foxa2 Delivered by Adeno‐Associated Virus 9 Ameliorate the Pathologies and Symptoms of Alzheimer’s Disease Models	23
The Impact Treatment Imbalance and Patient Enrichment has on Study Sample Size in Early/Mild Alzheimer’s Disease	23
Neuropathology of a patient with AD treated with low doses of verubecestat	23
Development of an artificial intelligence approach that employs genomic and brain imaging features to improve the diagnosis of Alzheimer’s Disease (AD)	23
Anti‐ulcer drug teprenone clinical trial	23
Strong effects of the ABCA1 agonist CS6253 on Amyloidβ42/40 ratio and lipoproteins in cynomolgus monkeys	23
PDE5 inhibitors against synaptic and cognitive impairment in Alzheimer’s disease and related dementia	23
Boswellic acids (K‐Vie^™) improves clinical cognitive scores and reduces systemic inflammation in patients with mild to moderate Alzheimer’s disease.	23
Posterior Cortical Atrophy: Primary Occipital Variant	23
Imaging and fluid biomarkers predictive of progression from mild cognitive impairment to dementia	23
Inhibiting tyrosine kinase c‐KIT as a therapeutic strategy for Alzheimer’s Disease	23
Efficacy and Safety of Adding Kami Guibi‐tang to Acetylcholinesterase Inhibitor for Cognitive Function in Mild Alzheimer’s Disease: A Pilot, Randomized, Double‐blind, Placebo‐controlled Trial	23
Identification and characterization of novel anti‐tau antibodies that inhibit tau‐seed mediated pathology in a P301S tauopathy mouse model Alzheimer’s Disease and tauopathies	23
The relationship between cerebrospinal fluid neurofilament light protein biomarker and cortical thinning across the spectrum of Alzheimer’s disease	23
Visualization of synaptic vesicle protein 2A in a rodent model of familial Alzheimer’s disease with a metabolically stable PET probe	23
SAGE‐718 in Patients With Mild Cognitive Impairment or Mild Dementia due to Alzheimer’s Disease: Results From the Phase 2 LUMINARY Study	23